Neuroscience and Behavioral Physiology

, Volume 39, Issue 5, pp 501–506 | Cite as

Use of Noben (idebenone) in the Treatment of Dementia and Memory Impairments without Dementia

  • K. V. Voronkova
  • M. N. Meleshkov

Noben (idebenone) at a dose of 120 mg per day for six months was used in the treatment of 35 patients aged 60–86 years with Alzheimer’s-type dementia, mixed dementia, and memory impairments not reaching the stage of dementia. Patients were assessed on the basis of data from somatic, neurological, and psychiatric investigations, as well as neuropsychological testing and a series of psychometric and other scales and tests, before and after treatment. Significant improvements in patients’ conditions on the MMSE were seen in patients with mild and moderate dementia. Improvements in daily activities were obtained in 27% of patients. Neuropsychological investigations demonstrated improvements in short-term and long-term memory and attention, with improvements in speech functions, performance of kinesthetic, spatial, and dynamic praxis tests, and in visuospatial gnosis, thought, and writing. On the CGI scale, positive treatment effects were obtained in 37% of patients, while 48% of patients remained in a stable state.

Key Words

dementia cognitive disorders treatment neuropsychological investigations Noben (idebenone) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. I. Gavrilov and G. A. Zharikov, “Galantamine (reminil) in the treatment of Alzheimer’s disease and vascular dementia,” Zh. Nevrol. Psikhiatr., 12, 59–65 (2003).Google Scholar
  2. 2.
    S. I. Gavrilov, “Alzheimer’s disease: diagnosis and treatment,” Vrach, 6, 1–4 (2004).Google Scholar
  3. 3.
    S. N. Illarioshkin et al., Inherited Ataxias and Paraplegias [in Russian], Medpress-Inform, Moscow (2006), p. 415.Google Scholar
  4. 4.
    V. N. Krasnov, A. P. Myzychenko, et al., “The new neurometabolic cerebroprotector idebenone: potential for use in psychiatry,” Sots. Klin. Psikhiatr., 1, 61–63 (2000).Google Scholar
  5. 5.
    R. Artuch, et al., “Friedreich’s ataxia: idebenone treatment in early stage patients,” Neuropediatrics, 33, No. 4, 190–193 (2002).PubMedCrossRefGoogle Scholar
  6. 6.
    B. Bergamasco, et al., “Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial,” Arch. Gerontol. Geriatr., 15, No. 3, 279–286 (1992).PubMedCrossRefGoogle Scholar
  7. 7.
    B. Bergamasco, et al., “Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type,” Funct. Neurobiol., 9, No. 3, 161–168 (1994).Google Scholar
  8. 8.
    G. Buyse et al., “Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring,” Neurobiology, 60, 1679–1681 (2003).Google Scholar
  9. 9.
    T. Erkinjuntti, G. Roman, and S. Gauthier, “Treatment of vascular dementia evidence from clinical trials with cholinesterase inhibitors,” J. Neurol. Sci., 226, No. 1–2, 63–66 (2004).PubMedCrossRefGoogle Scholar
  10. 10.
    J. G. Evans, G. Wilcock, and J. Birks, “Evidence-based pharmacotherapy of Alzheimer’s disease,” Int. J. Neuropsychopharmacol., 7, No. 3, 351–369 (2004).PubMedCrossRefGoogle Scholar
  11. 11.
    V. Geromel, N. Darin, D. Chretien, et al., “Coenzyme Q and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits,” Molec. Genet. Metab., 77, 21–30 (2002).CrossRefPubMedGoogle Scholar
  12. 12.
    H. Gutzmann et al., “Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study,” Pharmacopsychiatry, 35, 12–18 (2002).PubMedCrossRefGoogle Scholar
  13. 13.
    N. L. Keltner, A. L. Zielinski, and M. S. Hardin, “Drugs used for cognitive symptoms of Alzheimer’s disease,” Perspect. Psychiatr. Care, 37, No. 1, 31–34 (2001).PubMedCrossRefGoogle Scholar
  14. 14.
    D. H. McDaniel et al., “Idebenone: a new antioxidant – Part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants,” J. Cosm. Dermatol., 4, No. 1, 10–17 (2005).CrossRefGoogle Scholar
  15. 15.
    A. Merdente, G. Martorana, G. Minotti, and B. Giardina, “Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone),” Chem. Res. Toxicol., 11, No. 1, 54–63 (1998).CrossRefGoogle Scholar
  16. 16.
    T. Nabeshima, A. Nitta, K. Fuji, et al., “Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats,” Gerontology (Basel), 40, Suppl. 2, 46–56 (1994).Google Scholar
  17. 17.
    A. Napolitano, “Long-term treatment with idebenone and riboflavin in a patient with MELAS,” Neurol. Sci., 21, No. 5, Suppl., S981–S982 (2000).CrossRefGoogle Scholar
  18. 18.
    G. Nappi, “Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly,” Arch. Gerontol. Geriatr., 15, No. 3, 261–269 (1992).PubMedCrossRefGoogle Scholar
  19. 19.
    C. Scavini, A. Rozza, E. Lanza, et al., “Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats,” Eur. Neuropsychopharmacol., 6, 95–102 (1996).PubMedCrossRefGoogle Scholar
  20. 20.
    I. Schols et al., “Therapeutic strategies in Friedreich’s ataxia,” J. Neurol. Transm., 68, Suppl., 135–145 (2004).Google Scholar
  21. 21.
    U. Senin, “Idebenone in senile dementia of Alzheimer type: a multi-centre study,” Arch. Gerontol. Geriatr., 15, No. 3, 249–260 (1992).PubMedCrossRefGoogle Scholar
  22. 22.
    Y. Sugiyama and T. Fujita, “Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism,” FEBS Lett., 184, 48–51 (1985).PubMedCrossRefGoogle Scholar
  23. 23.
    L. J. Thai et al., “Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease,” Neurology, 61, No. 11, 1498–1502 (2003).Google Scholar
  24. 24.
    K. Yanagisawa “Natural progression of Alzheimer’s disease (AD): a perspective on possible therapies for advanced AD,” Rinsho Shinkeigaku, 44, No. 11, 921–923 (2004).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  • K. V. Voronkova
    • 1
    • 2
  • M. N. Meleshkov
    • 1
    • 2
  1. 1.Department of Neurology and NeurosurgeryRussian State Medical UniversityMoscowRussia
  2. 2.Litfond ClinicMoscowRussia

Personalised recommendations